cro.directory
← Home
Avigen Ltd logo

Avigen Ltd

Advancing immunotherapies with avidity intelligence

Avigen offers avidity-based profiling of live immune–target cell interactions for immunotherapy discovery and preclinical validation. Its platform supports TCR-T, CAR-T, and NK programmes across solid tumour indications. Headquartered in London, United Kingdom.

Phases

Species

Indications / Therapeutic Areas

Services

Modalities

About this organization

Overview

Avigen is a UK-based company that provides avidity intelligence for immunotherapy research. Its proprietary platform measures cellular avidity to identify the immune cells most likely to drive therapeutic success.

Services

  • Immunotherapy discovery: identifying target-specific leads among millions of potential candidates.
  • Immunotherapy validation: completing the immune cell data set and ranking candidates for translation.
  • Preclinical avidity insights: translational analysis from initial lead identification through pre-IND candidate confirmation.

Platform

  • Physiological relevance: captures live immune–target cell interactions that better reflect in vivo behaviour.
  • High throughput: analyses tens of thousands of single-cell interactions per run, scaling to millions.
  • Gentle: maintains cell viability and functionality for immediate downstream testing.
  • Fully adaptable: compatible with a range of adherent target cells and immune cell types, including TCR-T, CAR-T, and NK cells, across solid tumour indications.

Client testimonials describe high-quality data delivered on a rapid timeline and careful optimisation of difficult assay conditions.

Locations

  • White City (Scale Space)

    London · United Kingdom

Related companies

Similar profiles by shared services, phases, and indications.

Submit a verified review for this organization.

Markdown mirror: /companies/avigen.md